All Family Resources
All Clinician Resources

Update on a Promising New Drug to Treat JM: Vamorolone

Cure JM is making extraordinary progress in juvenile myositis (JM) research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.

Vamorolone is a steroid replacement with all the benefits of steroid treatment without devastating side effects. Vamorolone is currently in a clinical trial in Duchenne Muscular Dystrophy children.

Findings so far indicate improved safety relative to prednisone. Cure JM is working with vamorolone’s sponsor, ReveraGen, to design a clinical trial to test the drug’s safety in JM children. ReveraGen’s VP of Research, Eric Hoffmann, Ph.D., gives us an update on vamorolone and the status of a clinical trial in JM.

Cure JM Partner Researcher Uncovers New Biomarkers. Fionnuala McMorrow. University of Bath, UK

Cure JM-Funded Researcher Uncovers New Biomarkers

With your financial support, Cure JM is proud to have funded Fionnuala McMorrow, a Postgraduate Research Student in the Department of Life Sciences at the University of Bath, to embark on a critical research project. Fionnuala’s team analyzed blood samples from the UK to investigate two specific biomarkers (anti-CCAR1 and anti-Sp4) recently identified in U.S. patients with JDM and related conditions

Affordable and Accessible Treatments for JM

Affordable and Accessible Treatments for JM

Two special guest speakers, Michelle Vogel, MPA, IV Solutions RX, and Laurel Cherwin, BSN, RN, IgCN, Octapharma, shared information on navigating affordable treatments and care for JM patients.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Join Now
Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.